ABT-333
- CAS No.
- 1132935-63-7
- Chemical Name:
- ABT-333
- Synonyms
- CS-2000;ABT-333;Dasabuvir;ABT333; ABT 333;ABT-333/Dasabuvir;Dasabuvir (ABT-333);Dasabuvir-13C 15N2 D3;N-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide;Methanesulfonamide, N-[6-[5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]-2-naphthalenyl]-;N-[6-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Dasabuvir (ABT-333)
- CBNumber:
- CB62681991
- Molecular Formula:
- C26H27N3O5S
- Molecular Weight:
- 493.57
- MDL Number:
- MFCD27923655
- MOL File:
- 1132935-63-7.mol
| Melting point | >192oC (dec.) |
|---|---|
| Density | 1.317±0.06 g/cm3(Predicted) |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | Chloroform (Slightly, Heated), DMSO (Slightly), Methanol (Slightly, Heated) |
| pka | 8.52±0.30(Predicted) |
| form | Solid |
| color | Pale Brown to Light Brown |
| FDA UNII | DE54EQW8T1 |
| NCI Drug Dictionary | dasabuvir |
| ATC code | J05AP09 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H315-H319 |
| Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
ABT-333 price More Price(21)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 18482 | ABT-333 ≥98% | 1132935-63-7 | 5mg | $44 | 2024-03-01 | Buy |
| Cayman Chemical | 18482 | ABT-333 ≥98% | 1132935-63-7 | 10mg | $78 | 2024-03-01 | Buy |
| Cayman Chemical | 18482 | ABT-333 ≥98% | 1132935-63-7 | 25mg | $172 | 2024-03-01 | Buy |
| Cayman Chemical | 18482 | ABT-333 ≥98% | 1132935-63-7 | 50mg | $235 | 2024-03-01 | Buy |
| TRC | D193550 | Dasabuvir | 1132935-63-7 | 1mg | $50 | 2021-12-16 | Buy |
ABT-333 Chemical Properties,Uses,Production
Uses
Dasabuvir is an antiviral drug used in the treatment of chronic hepatitis C virus (HCV) infection.
Definition
ChEBI: A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as c rrhosis of the liver.
Clinical Use
Treatment of chronic hepatitis C infection
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: avoid concomitant use with
clarithromycin and telithromycin; concentration
possibly reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by
St John’s wort - avoid.
Antiepileptics: concentration reduced by
carbamazepine - avoid; concentration possibly
reduced by fosphenytoin, phenobarbital, phenytoin
and primidone - avoid.
Antifungals: concentration of both drugs increased
with ketoconazole and possibly itraconazole and
posaconazole - avoid.
Diuretics: concentration of furosemide increased
(reduce furosemide dose).
Immunosuppressants: increases concentration of
ciclosporin (reduce ciclosporin dose by a fifth);
everolimus (avoid); sirolimus and tacrolimus (reduce
dose and use only if benefit outweighs risk - see
SPC).
Lipid-regulating drugs: avoid with atorvastatin,
gemfibrozil and simvastatin; concentration of
rosuvastatin increased (reduce dose of rosuvastatin).
Oestrogens: avoid concomitant use with
ethinylestradiol.
Metabolism
Dasabuvir is mainly metabolised by CYP2C8 and to
a lesser extent by CYP3A. Seven metabolites were
identified in plasma. The most abundant plasma
metabolite was M1, which represented 21% of drugrelated radioactivity (AUC) in circulation following single
dose; it is formed via oxidative metabolism predominantly
by CYP2C8.
Following a 400 mg 14C-dasabuvir dose, approximately
94% of the radioactivity was recovered in faeces with
limited radioactivity (approximately 2%) in urine.
Unchanged dasabuvir accounted for 26.2% and M1 for
31.5% of the total dose in faeces. M1 is mainly cleared
through direct biliary excretion with the contribution of
UGT-mediated glucuronidation and, to a small extent,
oxidative metabolism.
ABT-333 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32480 | 60 |
| career henan chemical co | +86-0371-86658258 | sales@coreychem.com | China | 29914 | 58 |
| Hangzhou Cyanochem Co., Ltd. | +86 17788583750 | sales@cyanochem.com | CHINA | 283 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| Chongqing Chemdad Co., Ltd | +86-023-61398051 +8613650506873 | sales@chemdad.com | China | 39916 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
| AFINE CHEMICALS LIMITED | 0571-85134551 | info@afinechem.com | CHINA | 15377 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | 0551-65418684 +8618949823763 | sales@tnjchem.com | China | 25363 | 58 |
| Nanjing Doge Biomedical Technology Co., Ltd | +86-25-58227606 +86-15305155328 | sales@dogechemical.com | China | 4128 | 58 |
